<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Percutaneous minimally invasive radiofrequency (RF) ablation has not been described for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This image-guided modality is presented in 3 different settings for the treatment of refractory <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The first patient received RF ablation for the curative treatment of a solitary residual <z:e sem="disease" ids="C0240225" disease_type="Disease or Syndrome" abbrv="">hepatic mass</z:e> following rituximab-based chemotherapy for a posttransplantation <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> (PTLD) and is disease-free 4 years later </plain></SENT>
<SENT sid="3" pm="."><plain>The second patient received RF ablation for successful palliation of progressive follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> adjacent to the bladder wall following chemotherapy and maximum radiation </plain></SENT>
<SENT sid="4" pm="."><plain>The third patient received RF ablation for prevention of <z:e sem="disease" ids="C0001883" disease_type="Disease or Syndrome" abbrv="">airway obstruction</z:e> from progressive diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the right neck following chemotherapy and maximum radiation </plain></SENT>
<SENT sid="5" pm="."><plain>RF ablation may be clinically beneficial and should be considered for the treatment of local <z:hpo ids='HP_0002665'>lymphoma</z:hpo> that is refractory or not amenable to standard approaches </plain></SENT>
</text></document>